Company Encyclopedia
View More
name
ETFS Capital Ltd.
ZYUS.AU
News
View More

ZYUS Life Sciences Announces Closing Of Unit Offering

ZYUS Life Sciences Corp :ZYUS LIFE SCIENCES ANNOUNCES CLOSING OF UNIT OFFERING

Reuters·
Reuters·

ZYUS Life Sciences Advances Phase 2A Trial for Non-Opioid Cancer Pain Drug

ZYUS Life Sciences (TSE:ZYUS) is advancing its Phase 2A clinical trial, UTOPIA-1, to evaluate the safety and efficacy of Trichomylin softgel capsules for cancer-related pain management. This trial aims to provide alternative treatments to opioids, highlighting the potential of cannabinoids in oncology. Analysts rate ZYUS stock as a Buy with a price target of C$1.50. The company focuses on developing cannabinoid-based pharmaceuticals and securing regulatory approvals for non-opioid solutions.

Tip Ranks·
Tip Ranks·

ZYUS Life Sciences Sees Strategic Shareholding Shift

ZYUS Life Sciences (TSE:ZYUS) has reported a significant shift in its shareholding structure, with director Wayne Brownlee acquiring an additional 4,875,000 common share purchase warrants, raising his control to approximately 12.35% on a partially diluted basis. This strategic investment indicates Brownlee's intention to review and possibly adjust his holdings based on market conditions and company performance. ZYUS's year-to-date price performance is -13.19%, with a current market cap of C$46.29M.

Tip Ranks·
Tip Ranks·

Early Warning News Release Regarding the Issuance of Securities of ZYUS Life Sciences Corporation

On April 14, 2025, Wayne Brownlee, a director of ZYUS Life Sciences Corporation, acquired 4,875,000 common share purchase warrants, increasing his control to 12.35% on a partially diluted basis. The warrants, with an expiry date of March 28, 2027 and an exercise price of $0.80, were obtained in connection with unsecured loans to the company. Brownlee intends to review his investment and may adjust his holdings based on market conditions. An early warning report has been filed and is available on the company's SEDAR+ profile.

MorningStar·
MorningStar·